kenacid blue

RN given refers to cpd with unknown MF

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

1.	Dragović-Uzelac, Verica: 1 article (12/2019)
2.	Jurčević, Irena Landeka: 1 article (12/2019)
3.	Kmetič, Ivana: 1 article (12/2019)
4.	Kolarić, Josipa: 1 article (12/2019)
5.	Kovačević, Danijela Bursać: 1 article (12/2019)
6.	Lovrić, Vanja: 1 article (12/2019)
7.	Miletić, Marina: 1 article (12/2019)
8.	Murati, Teuta: 1 article (12/2019)
9.	Putnik, Predrag: 1 article (12/2019)
10.	Đikić, Domagoj: 1 article (12/2019)

1.	Melanoma (Melanoma, Malignant) 04/01/2008 - "In vitro antiproliferative activity was determined against tumor cell lines: human adenocarcinoma HeLa, human myelogenous leukemia K562, human malignant melanoma Fem-x, rested and stimulated normal immunocompetent cells (human peripheral blood mononuclear PBMC cells) using KBR test (Kenacid Blue Dye binding test). "
2.	Liver Neoplasms (Liver Cancer) 12/01/2019 - "To establish its anticancer properties, we exposed human liver cancer cells (Hep G2) to a range of blackthorn flower extract concentrations (10-200 µg/mL) and determined cytotoxic activity with the neutral red and kenacid blue methods after 24, 48, and 72 h of incubation. "
3.	Myeloid Leukemia (Leukemia, Myelocytic) 04/01/2008 - "In vitro antiproliferative activity was determined against tumor cell lines: human adenocarcinoma HeLa, human myelogenous leukemia K562, human malignant melanoma Fem-x, rested and stimulated normal immunocompetent cells (human peripheral blood mononuclear PBMC cells) using KBR test (Kenacid Blue Dye binding test). "
4.	Adenocarcinoma 04/01/2008 - "In vitro antiproliferative activity was determined against tumor cell lines: human adenocarcinoma HeLa, human myelogenous leukemia K562, human malignant melanoma Fem-x, rested and stimulated normal immunocompetent cells (human peripheral blood mononuclear PBMC cells) using KBR test (Kenacid Blue Dye binding test). "